Evaluating eribulin's ability to produce a cytokine immune response in lung cancer

2023/12/05 by Hinkle, Wyatt A., Hinz, Trista K., Gurulé, Natalia J. +1

paper · doi:10.25676/11124/178590

Abstract

This study aims to examine the ability of Eribulin, a non-taxane microtubule inhibitor, to induce a cytokine immune response similar to that of targeted TKI's in lung cancer cell lines, and furthermore to characterize the cytokine response to general growth arrest therapies compared to specific targeted protein kinase inhibitors such as TKI's.

Related

• Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity
• Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
• Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
• ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib
• Mechanistic study of PD-L1 regulation of metastatic proliferation in non-small cell lung cancer through modulation of IRE1α/XBP-1 signaling pathway in tumor-associated macrophages